
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
By moving uniformity monitoring back to the blender phase, blend variations that result from factors such as particle distribution and environmental temperature and humidity can be identified early.
over 24 years ago
The Usefulness of 0.45 µm–Rated Filter Membranesover 24 years ago
Outsourcing Outlookover 24 years ago
Bush Budget Combats Bioterrorism, Promotes Drug Safetyover 24 years ago
Liposomes: A Review




